Rising Pharma Holdings, Inc. is recalling two nationwide lots of its 25-milligram chlorthalidone tablets after the blood-pressure drug failed to meet potency standards, raising the risk that patients taking the pills could experience uncontrolled hypertension. The affected products, manufactured by Inventia Healthcare Limited in India, are sold in 100-count and 1,000-count bottles under NDC codes 64980-599-01 and 64980-599-10. The voluntary recall is now being tracked through the FDA’s enforcement reporting system, but key details about root cause and classification remain absent from public records.
Why subpotent chlorthalidone tablets put patients at direct risk
Chlorthalidone is a thiazide-like diuretic prescribed to many Americans for high blood pressure and edema. It works by helping the kidneys eliminate excess salt and water, which in turn lowers blood volume and blood pressure. When a tablet contains less active ingredient than its label promises, the drug may not provide the expected blood-pressure reduction, especially for patients stabilized on a specific dose.
For individuals who rely on a single daily tablet to keep readings in a safe range, a subpotent pill is not a minor inconvenience. It is a silent gap in treatment that can allow blood pressure to climb without obvious symptoms. Uncontrolled hypertension over days or weeks raises the chance of stroke, heart attack, or kidney damage, particularly in older adults and people with existing cardiovascular disease. Because patients cannot tell by appearance whether a tablet is subpotent, the risk persists until the lot is identified and removed from use.
The two recalled NDC codes correspond to prescription labeling for 25 mg chlorthalidone tablets distributed by Rising Pharma Holdings, Inc., based in East Brunswick, New Jersey. The tablets were manufactured by Inventia Healthcare Limited, an India-based contract producer. Drug recalls of this type are typically voluntary actions initiated by the distributing company after internal testing or complaints reveal a quality defect. The FDA’s role is to monitor the recall, assess the health hazard, and assign a classification that signals how serious the risk is to consumers.
What FDA enforcement records show and what they do not
The FDA publishes recall actions through its enforcement reports, which are updated after a formal hazard assessment. These reports generally list the product name, lot numbers, reason for recall, and classification. However, as of early July 2026, no machine-readable record in the openFDA drug enforcement database supplies the exact classification date or a detailed root-cause analysis for these specific chlorthalidone lots. That gap matters because the classification level, ranging from Class I (most dangerous) to Class III (least), determines how aggressively the FDA expects the company to retrieve remaining product from pharmacies, wholesalers, and health systems.
Without a posted classification, health-care providers and patients are left to infer the seriousness of the problem from limited information. Subpotent blood-pressure medicine can plausibly fit into the more serious end of the spectrum, particularly for high-risk patients, but the final determination rests with FDA risk assessors. The absence of a public root-cause narrative also leaves open whether the issue stemmed from a one-time manufacturing deviation, such as an error in mixing or compression, or from a systemic failure in the quality system at the manufacturing site.
Neither Inventia Healthcare nor Rising Pharma has released a detailed public statement explaining the deviation that produced subpotent tablets. In the meantime, the FDA’s MedWatch program accepts reports of therapeutic failures, meaning patients or clinicians who suspect their chlorthalidone stopped working can submit a report directly to the agency. Those case reports can help regulators detect patterns, such as clusters of elevated blood pressure readings tied to specific lot numbers, even before full investigations are complete.
Open questions about Rising Pharma’s supply chain and oversight
The recall raises broader questions about how Rising Pharma oversees its overseas manufacturing partners. As the distributor of record, Rising is responsible for ensuring that products released under its label meet U.S. quality standards, regardless of where they are made. When a lot is found to be subpotent, investigators typically review batch records, equipment calibration logs, and stability data to determine whether the failure was confined to specific lots or could affect additional strengths or dosage forms.
At this stage, public records do not indicate whether Rising or Inventia has expanded testing of retained samples from adjacent lots, or whether any other strengths of chlorthalidone have been flagged for closer scrutiny. Pharmacies and health systems often depend on direct notices from manufacturers or wholesalers to identify affected inventory, but those communications are not routinely posted for public review. That makes FDA enforcement listings one of the few centralized windows into how far a recall extends.
Clinicians managing patients on chlorthalidone face practical decisions while details remain scarce. For patients whose tablets match the recalled NDC codes and lot numbers, the usual advice is to contact the dispensing pharmacy for replacement and to avoid abruptly stopping therapy without a substitute. For others experiencing unexplained loss of blood-pressure control, clinicians may consider checking product lot information, adjusting therapy, and documenting any suspected product-quality issues for regulatory follow-up.
To stay informed about changes to the recall status, health-care professionals and pharmacists can use the FDA’s subscription tools, including the email notification system that distributes updates on new and modified enforcement actions. Until FDA posts a final classification and a clearer account of what went wrong in production, the chlorthalidone recall underscores a persistent vulnerability in the generic drug supply: when quality slips, the first signal may be a patient whose blood pressure quietly rises, long before the paperwork catches up.
